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Background: the impact of human immunodeﬁciency virus type 1 (HIV-1) on lung function
is  well known and associated with a reduction in pulmonary ventilation. Moreover, the
use  of highly active antiretroviral therapy has been associated with mitochondrial dysfunc-
tion  and decreased muscle strength. However, there is scarce information about the factors
associated  with inspiratory muscle weakness in these patients.
Objective:  the purpose of the present study was to investigate the factors associated with
inspiratory  muscle weakness in patients with HIV-1.
Methods: two-hundred ﬁfty seven patients with HIV-1 were screened and categorized into
two groups: (1) IMW+ (n = 142) and (2) IMW− (n = 115). Lung function (FEV1, FVC and
FEV1/FVC), maximum inspiratory pressure, distance on the six-minute walk test and CD4
cell  count were assessed.
Results:  the mean duration of HIV infection was similar in the two groups. The follow-
ing  variables were signiﬁcantly different between groups: mean duration of highly active
antiretroviral  therapy (81 ± 12 in IMW+ versus 38 ± 13 months in IMW−; p = 0.01), and CD4
cell  count (327 ± 88 in IMW+ versus 637 ± 97 cells/mm3 in IMW−; p = 0.02). IMW+ presented
reduced  lung function (FEV1, FVC, FEV1/FVC).
Conclusion: patients with IMW+ had lower distance on the six-minute walk test in com-parison  to the IMW− group. The duration of highly active antiretroviral therapy, distance
traveled  on the 6MWT and CD4 count were determinants of IMW in patients with HIV.
©  2015 Published by Elsevier Editora Ltda.
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Introduction
The use of highly-active antiretroviral therapy (HAART) has
improved  the prognosis of patients infected by the human
immunodeﬁciency virus type 1 (HIV-1).1–4 A previous study
has  demonstrated that such individuals exhibit progressive
skeletal muscle dysfunction affecting exercise performance.5
However, other studies suggest that mitochondrial function
may  be adversely affected by the biochemical changes that
occur  in HIV-1 infection6 or by the use of HAART.7 These
factors help explain the inspiratory muscle weakness (IMW)
found  in patients with HIV-1, as evidenced by reduced maxi-
mum  inspiratory pressure (MIP <70% of predicted value).8–11
The mechanisms responsible for limited exercise capacity
include  abnormalities in the central hemodynamics (sluggish
blood  ﬂow and faster oxygen extraction in peripheral tissues)
as  well as autonomic, vascular and respiratory responses to
exercise.11 However, studies have shown that even asymp-
tomatic patients with HIV-1 exhibit generalized wasting and
signiﬁcant  loss of functional capacity, as demonstrated by
a  shorter distance traveled on the six-minute walk test
(6MWT).5,12
Other factors linked to physical de-conditioning include
the  chronic nature of the disease, anemia, diabetes, infec-
tion  and peripheral oxidative dysfunction related to the use
of  nucleoside reverse transcriptase inhibitors.8,10 These fac-
tors  result in exaggerated ventilatory response to exercise,
with  reduced lung compliance10 and progressive recruitment
of  inspiratory and expiratory muscles, resulting in inspiratory
muscle  fatigue during exercise. The inspiratory muscles may
also  be adversely affected by changes in and resistance to
contractile  properties13,14 due to chronic oxidative stress and
infection.15
According to Schulz et al.16 impaired respiratory mus-
cle  function may  contribute to the unexplained shortness of
breath  found in patients with HIV. However, no previous study
has  addressed the determinants of IMW  in such individuals.
Thus,  the aim of the present study was  to investigate possible
factors  associated with IMW  in patients with HIV.
Material  and  methods
Subjects
A comparative study was  carried out involving 257 patients
with  HIV-1 receiving HAART and physically inactive for at least
six  months. Patients were recruited from a national reference
center  for acquired immunodeﬁciency syndrome (AIDS) in
Brazil.  The inclusion criteria were  a diagnosis of HIV infection,
clinical  stability (without hemodynamic instability or pres-
ence  of opportunistic disease) and no change in antiretroviral
regimen in the previous three months. The exclusion criteria
were  unstable angina, myocardial infarction, chronic lung dis-
ease, or cardiac surgery in the previous three months; chronic
metabolic  or orthopedic condition treated with steroids or
hormones;  undergoing chemotherapy for cancer; history of
lung  disease (forced vital capacity [FVC] <80% of predicted
value  and/or forced expiratory volume in 1 s [FEV1] <70% 2 0 1 5;1  9(1):1–7
of  predicted value); history of exercise-induced asthma; and
smoking  habit. This study received approval from the Human
Research  Ethics Committee of the Hospital Clinicas de Porto
Alegre  (Brazil) under process number 240.254 and all subjects
signed  a statement of informed consent.
Protocol
The medical history of eligible patients was  recorded and the
subjects  were submitted to an initial physical examination,
resting electrocardiogram, the determination of inspiratory
muscle function and the 6MWT. The patients also provided
blood  samples for fasting glucose, total-, LDL- and HDL-
cholesterol, CD4 and CD8 counts. The participants had two
came  to the laboratory on day 1 and 48 h thereafter. The
patients had to undergo a protocol for maximal inspira-
tory  muscle strength (MIP) evaluation and were  categorized
into  two groups: (1) with maximal inspiratory muscle dys-
function  denominated inspiratory muscle weakness positive
(IMW+,  MIP <70% of predicted value);11,16,17 and (2) without
inspiratory muscle weakness, i.e., with MIP preserved denom-
inated  IMW− (MIP >70% of predicted value). The 6MWT  was
performed  three times on each evaluation day for the determi-
nation  of the maximum distance traveled and reproducibility.
Lung  function
Lung function assessment was  performed using the CPF Sys-
tem  (Medical Graphics-MGC, St. Paul, MN), with air ﬂow
measured using a calibrated Pitot tube (PreVent, Pneumotach).
FVC  (in liters), FEV1 (in liters), FEV1/FVC and inspiratory capac-
ity  (in liters) were recorded as recommended by the American
Thoracic Society.18 The results were expressed as absolute and
percentage  of predicted value. Inspiratory muscle function
testing  was  performed using a pressure transducer system
(POWERbreathe K5, Northﬁeld Road, Southam, Warwickshire,
UK).  Maximum static inspiratory pressure was  determined in
deep inspiration starting from residual volume. The highest
pressure  of six measurements was  used for analysis.
Six-Minute  Walk  Test
The 6MWT was  performed in an indoor corridor measuring
25  m in length, following recommendations by Guyatt et al.19
The participants were instructed to walk from one end to the
other  of the corridor as many  times as possible in six minutes.
At  the end of the test, the physical therapist measured the total
distance traveled. Reproducibility was determined in a sample
of  the 257 patients and the difference in distance between the
two  tests was  less than 5%. The maximum distance traveled
was  used to assess submaximal functional capacity. Patients
self-graded their degree of dyspnea during the test using the
Borg  scale.17
Statistical  analysisThe data were  analyzed with the Statistical Package for the
Social  Sciences (version 19.0, SPSS, Chicago, IL). Descriptive
data  are presented as mean ± standard deviation. Data of the
two  groups were compared by one-way repeated-measures
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Table 1 – Characteristics of participants.
Characteristics All patients (n = 257) IMW+ (n = 142) IMW− (n = 115) p-Value
Demographic/anthropometric
Age (years) 45 ± 11 46.5 ± 11 49.2 ± 10 0.24
Sex (male/female) 53/18 35/10 18/8 0.77
BMI (kg/m2) 23 ± 3 23 ± 4 25 ± 4 0.42
Fasting Glucose (mg/dL) 99 ± 22 91 ± 25 86 ± 16 0.12
Total cholesterol (mg/dL) 180 ± 40 176 ± 42 189 ± 37 0.23
HDL-cholesterol (mg/dL) 43 ± 13 46  ± 14 39  ± 9 0.11
LDL-cholesterol (mg/dL) 110 ± 45 105  ± 34 118  ± 37 0.29
Hemodynamics
MBP (mm Hg) 90 ± 16 98 ± 12 90 ± 18 0.35
HR (beats min−1) 77 ± 7 88 ± 8 76 ± 10 0.74
Duration of HIV (months) 122 ± 18 104 ± 12 111 ± 21 0.34
Duration of HAART (months) 56 ± 27 81 ± 12a 38 ± 13 0.01
Virology
CD4 count (cells/mm3) 536 ± 72 327 ± 88a 637 ± 97 0.02
CD8 count (cells/mm3) 1098 ± 444 1086 ± 480 1124 ± 358 0.25
CD4/CD8 ratio 0.48 ± 0.18 0.31 ± 0.04a 0.56 ± 0.09 0.01
CD4 nadir (cells/mm3)
Median (interquartile range) 245 (140–368) 90 (19–144)a 270 (159–354) 0.03
Viral load (log) 2.1 (1.7–3.5) 2.5 (1.8–3.6) 2.1 (1.5–3.4) 0.55
Viral load (≤50 cells/mm3; %) 71 67b 92 0.04
Lung function
FEV1 (L) 3.02 ± 0.45 2.66 ± 0.46a 2.88 ± 0.67 0.02
FEV1 (% of predicted) 95 ± 10 85 ± 6a 93 ± 8 0.03
FVC (% of predicted) 101 ± 12 92 ± 13a 102 ± 9 0.03
FEV1/FVC 94 ± 5 92 ± 8 91 ± 9 0.67
Inspiratory muscle function
MIP  (cm H2O) 80 ± 12 45 ± 12a 90 ± 17 0.01
MIP (% predicted) 77 ± 11 46 ± 14 89 ± 12 0.01
Exercise
6MWD (m) 445 ± 65 265 ± 38a 452 ± 67 0.01
6MWD (% of predicted) 95 ± 22 45 ± 18a 91 ± 12 0.01
Continuous variables expressed as mean ± standard deviation; categorical variables expressed using chi-square or Fisher’s exact test.
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MBP, mean blood pressure; HR, heart rate; FEV1, forced
expiratory volume in 1st min; FVC, forced vital capacity; FEV1/FVC, forced expiratory volume in 1st min to forced vital capacity ratio; MIP,
maximal inspiratory pressure; 6MWD, distance traveled on six-minute walk test; HAART, highly active antiretroviral therapy.
a Signiﬁcant difference in comparison to other two groups.
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Fig. 1 – The CONSORT-ﬂow diagram of patients in the study.
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Fig. 2 – Scattergram of the association between maximum
inspiratory pressure (MIP) and CD4 count (cells/mm3) for all
subjects. Open circles represent patients without
inspiratory muscle weakness. Filled circles represent
patients with inspiratory muscle weakness. r = Pearson’s
correlation coefﬁcient.
No abnormalities were  found regarding hemodynamics. The
IMW+  group had higher fasting glucose. Time elapsed since
the  diagnosis of HIV infection was  not signiﬁcantly differ-
ent  between groups. IMW+  patients had been under HAART
for  a longer period of time, had a signiﬁcantly lower CD4
count,  but no difference in the CD8 count, resulting in a lower
CD4/CD8  ratio. The lung function was  more  compromised in
IMW+ compared to IMW−  (FEV1: 85 ± 6 vs. 93 ± 8% of pre-
dicted; p = 0.03; FVC: 92 ± 13 vs. 102 ± 9% of predicted; p = 0.03),
but  within normality without differences between FEV1/FVC.
The  IMW+  group had lower MIP  (45 ± 12 vs. 90 ± 17 cm H2O;
p  = 0.01) and traveled a shorter distance on the 6MWT (265 ± 38
vs.  452 ± 67 m;  p = 0.01) in comparison to the IMW− group.
The therapeutic regimens consisted of two nucleoside
analog reverse transcriptase inhibitors plus one protease
inhibitor, with or without low-dose ritonavir (25%), or a non-
nucleoside  reverse transcriptase inhibitor (75%). The most
common  HAART combination in the IMW+  group was zidovu-
dine,  lamivudine and efavirenz, which differed from that of
patients  in the IMW−  group. MIP  was  closely associated with
the  CD4 cell count in all patients (r = 0.761; p < 0.001; Fig. 2). In
the  stepwise multiple regression analysis (Table 2), the CD4
Table 2 – Results of stepwise multiple regression
analysis of maximum inspiratory pressure.
Dependent variable Independent variable  ˇ ra
6MWD HAART duration −0.62 0.68
MIP  0.66
CD4  count 0.78
MIP, maximum inspiratory pressure; HAART duration, duration of
highly active antiretroviral therapy; 6MWD, distance on six-minute
walk test; ˇ, standardized partial regression coefﬁcient; r, multiple
correlation coefﬁcient.
a p < 0.001. 2 0 1 5;1  9(1):1–7
count was  a signiﬁcant determinant of 6MWT.  The total vari-
ance  explained by this model was  56% (p < 0.001).
Table 3 displays the CD4 cell counts in the IMW+ and
IMW− groups. Eighty-eight patients in the IMW+  group
had  <200 cells/mm3 and 54 had >200 cells/mm3. In the
IMW− group, 49 patients had <200 cells/mm3 and 66 had
>200  cells/mm3. Interestingly, the combination of IMW and
CD4  count <200 cells/mm3 altered pulmonary function, inspi-
ratory  muscle strength and distance traveled on the 6MWT
in  comparison to the absence of IMW  and CD4 count
>200 cells/mm3.
Discussion
The present study is the ﬁrst to describe the determinants
of inspiratory muscle weakness (IMW) in patients with HIV.
Inspiratory  muscle dysfunction is related to the severity of
HIV  infection.16,20 The present data reveal that 55% of HIV-
infected patients presented IMW in a sample of clinically
stable patients. This ﬁnding is compatible with previous
studies.16,21 However, in contrast to the present study, these
studies  had smaller sample sizes.
IMW was striking in the patients analyzed. This response
is  dependent on hemodynamic and clinical variables as well
as  changes in diaphragm morphology.11 Moreover, the longer
duration  of HAART in IMW+ patients, associated with both
the  distance traveled on the 6MWT and CD4 cell count, might
have  caused higher toxicity in these patients compared to
IMW−  patients. However, the effects of HIV infection on respi-
ratory  muscles function have not been well characterized in
the  literature. Our study has shown that inspiratory muscle
dysfunction can lead to a reduction in lung function, even in
clinically  stable patients (CD4 >200).22 Previous studies have
described  that such a reduction is associated with lower CD4
count,23,24 which explains the increase in the frequency of
respiratory symptoms combined with dyspnea in patients
with  HIV. Moreover, impaired lung function is considered to
be an important predictor of increased respiratory mortality
and  closely associated with adverse cardiovascular events.25
HIV infection is associated with progressive depletion
of CD4T lymphocytes and defective HIV-speciﬁc T-cell
responses.26 Persistent immune activation plays a central role
in  driving CD4 T-cell depletion and progression to AIDS.27,28
The authors of the present study believe that severe infection
and  reactive oxygen species are required for the molecular
cascades that eventually produce myoﬁber atrophy of the
diaphragm, which may  favor IMW  in patients with HIV.
In  the present study, MIP was  closely correlated with the
distance  traveled on the 6MWT (r = 0.61; p < 0.001) and CD4
cell  count (r = 0.73; p < 0.001), independently of IMW,  which
suggests an important combination with the inﬂammatory
response. Moreover, associations were  found between MIP and
duration  of HAART (r = −0.62; p < 0.001) as well as between the
distance  traveled on the 6MWT and fasting glucose (r = −0.65,
p  = 0.02). Studies have suggested that inadequate glucose
control may  be linked to inﬂammation and decreased lung
function  in individuals with diabetes.29 The authors of the
present  study agree with the hypothesis that IMW  or dys-
function  occurs in the course of HIV infection. Moreover, the
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Table 3 – Comparative assessment of pulmonary function, inspiratory muscle strength and distance walked in different
groups according to CD4 count.
IMW+ IMW−
CD4 <200 (n = 88) CD4  >200 (n = 54) CD4  <200 (n = 49) CD4 >200 (n = 66)
FEV1 (L) 1.88  ± 0.66a,b 2.58 ± 0.45 2.88 ± 0.49c 3.01 ± 0.56
FEV1 (% of predicted) 83  ± 5a 90 ± 8 95 ± 12 96 ± 9
FVC (% of predicted) 95 ± 12 95 ± 7 98 ± 8 102 ± 12
FEV1/FVC 88 ± 6a,b 94 ± 5 96 ± 5c 94 ± 8
MIP (cm H2O) 45 ± 12a,b 68 ± 15 80 ± 13c 97 ± 20
MIP (% of predicted) 46 ± 14a,b 69 ± 12 82 ± 18 98 ± 19
6MWD (m) 265 ± 38a,b 301 ± 44 349 ± 49c 452 ± 67
6MWD (% predicted) 45 ± 18a,b 52 ± 14 81 ± 27 95 ± 29
Viral load (%)
≤50  41a 69 60 83
Data expressed as mean ± standard deviation.
IM,  inspiratory muscle weakness; FEV1, forced expiratory volume in 1st min; FVC, forced vital capacity; FEV1/FVC, forced expiratory volume in
1st min to forced vital capacity ratio; MIP, maximal inspiratory pressure; 6MWD, distance traveled on six-minute walk test.
a Signiﬁcant difference in overall comparison (p < 0.001).
b Comparison of CD4 below 200 cells/mm3 in IMW+ and IMW− (p < 0.01).
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uthors believe that a reduction in CD4 cell count results in
MW  and exercise intolerance.
A  number of mechanisms have been suggested to explain
he  reduction in inspiratory muscle strength in patients with
IV,  such as reduced cross-sectional area of all types of mus-
le  ﬁber in the diaphragm and muscles of the ribcage, type I
ber atrophy, changes in the type I to type IIb ﬁber ratio in
he  diaphragm,30–32 a reduced number of actin-myosin cross-
ridges  in the diaphragm,33 and an abnormal intracellular
a2+ proﬁle.30,31 The same applies for potential mechanisms
eading to inspiratory muscle dysfunction, impaired car-
iac  function,9 a reduction in oxidative enzymes15,34 and
mpaired mitochondrial replication through the inhibition of
itochondrial  DNA gyrase by zidovudine,16,35 which could
urther  compromise the inspiratory muscles. In the present
tudy,  the prevalence of IMW  coincided with the use of
idovudine. Evidence suggests that zidovudine and tenofovir
esult  in signiﬁcant myopathy.21,35,36 Although the patients
n  the present study exhibited IMW,  the authors believe
hat  systemic biochemical abnormalities may  occur, result-
ng  in inspiratory muscle dysfunction in patients with HIV.
tudies  have reported a lack of l-carnitine, which lim-
ts  the intra-mitochondrial transport of long-chain fatty
cids,  leading to a change in energy metabolism6 and
mpairment of diaphragm contractions. Studies have also
uggested  that an impaired oxidation reduction mecha-
ism  in muscle may  contribute to oxidative stress in the
iaphragm.13,14,37–39
Shortness of breath is often associated with exercise intol-
rance  and it has been suggested that IMW may  be an
mportant contributing cause to the sensation of dyspnea,16
s well as to a shorter the distance traveled on the 6MWT in
atients  with HIV. Several studies have reported a relation-
40,41hip  between anemia and fatigue in such patients. The
istance  traveled on the 6MWT  in the present study provides
urther  evidence that infections could result in decreased exer-
ise  capacity. < 0.01).
Surprisingly, a CD4 count <200 cell/mm3 affected inspira-
tory  muscle strength and the distance traveled on the 6MWT,
which  supports our hypothesis that infection is an important
factor  to exercise intolerance in patients with HIV.
The  present study has a limitation that should be
addressed. No cardiopulmonary exercise test was  performed,
which  would have conﬁrmed exercise intolerance. However,
a  submaximal exercise text (6MWT) was  used.5 The distance
traveled  on the 6MWT has demonstrated important associa-
tions  with the loss of muscle mass, generalized wasting and
weaker  handgrip strength.12,42 These associations have pre-
viously  been evaluated in patients with chronic heart failure
and  IMW.11,19 In our study, IMW was assessed by non-invasive
technique as described in other published studies. Perhaps
we  should have used more  invasive measures such as tension
time  diaphragmatic index or twitch Pdi.
The ﬁndings of the present study demonstrate that
patients with HIV infection have signiﬁcant exercise limita-
tions  resulting from IMW. The underlying pathomechanisms,
responses to treatment, and the potential role of IMW as a
prognostic  marker of respiratory muscle dysfunction merit
further  investigation.
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